Effects of the second-generation synthetic lipid A analogue E5564 on responses to endotoxin equine whole blood and monocytes

American Journal of Veterinary Research

Volumn 69, Issue 6, 2008, Pages 796-803

  Figueiredo, Monica D ^a   Moore, James N ^a   Vandenplas, Michel L ^a   Sun, Wan Chun ^a   Murray, Thomas F ^b  

^a UNIVERSITY OF GEORGIA   (United States)

^b CREIGHTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ENDOTOXIN; ERITORAN; INTERLEUKIN 10; INTERLEUKIN 1BETA; INTERLEUKIN 6; LIPID A DERIVATIVE; LIPOPOLYSACCHARIDE; MESSENGER RNA; PROCOAGULANT; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ARTICLE; BLOOD SAMPLING; CELL ISOLATION; CELL LYSATE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG EFFECT; ENDOTOXEMIA; ESCHERICHIA COLI; GENE EXPRESSION; HORSE; INHIBITION KINETICS; MONOCYTE; NONHUMAN; NUCLEOTIDE SEQUENCE; REAL TIME POLYMERASE CHAIN REACTION; SUPERNATANT; VENOUS BLOOD;

ANIMALS; ANTI-INFLAMMATORY AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; HORSES; INHIBITORY CONCENTRATION 50; INTERLEUKIN-10; INTERLEUKIN-1BETA; INTERLEUKIN-6; LEUKOCYTES, MONONUCLEAR; LIPID A; LIPOPOLYSACCHARIDES; POLYMERASE CHAIN REACTION; RNA, MESSENGER; TUMOR NECROSIS FACTOR-ALPHA;

EQUIDAE; ESCHERICHIA COLI;

EID: 45949103247     PISSN: 00029645     EISSN: None     Source Type: Journal    
DOI: 10.2460/ajvr.69.6.796     Document Type: Article

References (52)

1. Tinker MK, White NA, Lessard P, et al. Prospective study of equine colic incidence and mortality. Equine Vet J 1997;29:448-453.
2. Werners AH, Bull S, Fink-Gremmels J. Endotoxaemia: a review with implications for the horse. Equine Vet J 2005;37:371-383.
3. Moore JN, Barton MH. Treatment of endotoxemia. Vet Clin North Am Equine Pract 2003;19:681-695.
4. Hawkins LD, Christ WJ, Rossignol DP. Inhibition of endotoxin response by synthetic TLR4 antagonists. Curr Top Med Chem 2004;4:1147-1171.
5. Takayama K, Qureshi N, Beutler B, et al. Diphosphoryl lipid A from Rhodopseudomonas sphaeroides ATCC 17023 blocks induction of cachectin in macrophages by lipopolysaccharide. Infect Immun 1989;57:1336-1338.
6. Qureshi N, Takayama K, Kurtz R. Diphosphoryl lipid A obtained from the nontoxic lipopolysaccharide of Rhodopseudomonas sphaeroides is an endotoxin antagonist in mice. Infect Immun 1991;59:441-444.
7. Golenbock DT, Hampton RY, Qureshi N, et al. Lipid A-like molecules that antagonize the effects of endotoxins on human monocytes. J Biol Chem 1991;266:19490-19498.
8. Manthey CL, Perera PY, Qureshi N, et al. Modulation of lipopolysaccharide-induced macrophage gene expression by Rhodobacter sphaeroides lipid A and SDZ 880.431. Infect Immun 1993;61:3518-3526.
9. Lei MG, Qureshi N, Morrison DC. Lipopolysaccharide (LPS) binding to 73-kDa and 38-kDa surface proteins on lymphoreticular cells: preferential inhibition of LPS binding to the former by Rhodopseudomonas sphaeroides lipid A. Immunol Lett 1993;36:245-250.
10. Zuckerman SH, Qureshi N. In vivo inhibition of lipopolysaccharide-induced lethality and tumor necrosis factor synthesis by Rhodobacter sphaeroides diphosphoryl lipid A is dependent on corticosterone induction. Infect Immun 1992;60:2581-2587.
11. Kobayashi S, Kawata T, Kimura A, et al. Suppression of murine endotoxin response by E5531, a novel synthetic lipid A antagonist. Antimicrob Agents Chemother 1998;42:2824-2829.
12. Loppnow H, Libby P, Freudenberg M, et al. Cytokine induction by lipopolysaccharide (LPS) corresponds to lethal toxicity and is inhibited by nontoxic Rhodobacter capsulatus LPS. Infect Immun 1990;58:3743-3750.
13. Christ WJ, Asano O, Robidoux AL, et al. E5531, a pure endotoxin antagonist of high potency. Science 1995;268:80-83.
14. Bunnell E, Lynn M, Habet K, et al. A lipid A analog, E5531, blocks the endotoxin response in human volunteers with experimental endotoxemia. Crit Care Med 2000;28:2713-2720.
15. Bryant CE, Ouellette A, Lohmann K, et al. The cellular Toll-like receptor 4 antagonist E5531 can act as an agonist in horse whole blood. Vet Immunol Immunopathol 2007;116:182-189.
16. Lohmann KL, Vandenplas M, Barton MH, et al. Lipopolysaccharide from Rhodobacter sphaeroides is an agonist in equine cells. J Endotoxin Res 2003;9:33-37.
17. Rossignol DP, Christ WJ, Hawkins LD, et al. Synthetic endotoxin antagonists. In: Brade H, Opal SM, Vogel SN, et al, eds. Endotoxin in health and disease. New York: Marcel Dekker, 1999;699-717.
18. Rossignol DP, Lynn M. Antagonism of in vivo and ex vivo response to endotoxin by E5564, a synthetic lipid A analogue. J Endotoxin Res 2002;8:483-488.
19. Lynn M, Wong YN, Wheeler JL, et al. Extended in vivo pharmacodynamic activity of E5564 in normal volunteers with experimental endotoxemia. J Pharmacol Exp Ther 2004;308:175-181.
20. Okano S, Hurley DJ, Vandenplas ML, et al. Effect of fetal bovine serum and heat-inactivated fetal bovine serum on microbial cell wall-induced expression of procoagulant activity by equine and canine mononuclear cells in vitro. Am J Vet Res 2006;67:1020-1024.
21. Morris DD, Moore JN, Fischer K, et al. Endotoxin-induced tumor necrosis factor activity production by equine peritoneal macrophages. Circ Shock 1990;30:229-236.
22. Arunlakshana O, Schild HO. Some quantitative uses of drug antagonists. Br J Pharmacol Chemother 1959;14:48-58.
23. MacKay D. How should values of pA2 and affinity constants for pharmacological competitive antagonists be estimated? J Pharm Pharmacol 1978;30:312-313.
24. Morris DD. Endotoxemia in horses. A review of cellular and humoral mediators involved in its pathogenesis. J Vet Intern Med 1991;5:167-181.
25. Mullarkey M, Rose JR, Bristol J, et al. inhibition of endotoxin response by E5564, a novel Toll-like receptor 4-directed endotoxin antagonist. J Pharmacol Exp Ther 2003;304:1093-1102.
26. Wong YN, Rossignol D, Rose JR, et al. Safety, pharmacokinetics, and pharmacodynamics of E5564, a lipid A antagonist, during an ascending single-dose clinical study. J Clin Pharmacol 2003;43:735-742.
27. Henry MM, Moore JN. Endotoxin-induced procoagulant activity in equine peripheral blood monocytes. Circ Shock 1988;26:297-309.
28. Mackman N. Role of tissue factor in hemostasis and thrombosis. Blood Cells Mol Dis 2006;36:104-107.
29. Henry MM, Moore JN. Clinical relevance of monocyte procoagulant activity in horses with colic. J Am Vet Med Assoc 1991;198:843-848.
30. Osterud B, Bjorklid E. The tissue factor pathway in disseminated intravascular coagulation. Semin Thromb Hemost 2001;27:605-617.
31. Vickers J, Russwurm. S, Dohm B, et al. Monocyte tissue factor (CD142) and Mac-1 (CD11b) are increased in septic patients. Thromb Haemost 1998;79:1219-1220.
32. Werners AH, Bull S, Vendrig JC, et al. Genotyping of Toll-like receptor 4, myeloid differentiation factor 2 and CD-14 in the horse: an investigation into the influence of genetic polymorphisms on the LPS induced TNF-alpha response in equine whole blood. Vet Immunol Immunopathol 2006;111:165-173.
33. Baskett A, Barton MH, Norton N, et al. Effect of pentoxiyflline, flunixin meglumine, and their combination on a model of endotoxemia in horses. Am J Vet Res 1997;58:1291-1299.
34. Beutler B, Milsark IW, Cerami AC. Passive immunization against cachectin/ tumor necrosis factor protects mice from lethal effect of endotoxin. Science 1985;229:869-871.
35. Mei YQ Ji Q, Liu H, et al. Study on the relationship of APACHE III and levels of cytokines in patients with systemic inflammatory response syndrome after coronary artery bypass grafting. Biol Pharm Bull 2007;30:410-414.
36. Morris DD, Moore JN, Crowe N. Serum tumor necrosis factor activity in horses with colic attributable to gastrointestinal tract disease. Am J Vet Res 1991;52:1565-1569.
37. Morris DD, Moore JN. Tumor necrosis factor activity in serum from neonatal foals with presumed septicemia. J Am Vet Med Assoc 1991;199:1584-1589.
38. Barton BE. IL-6: insights into novel biological activities. Clin Immunol Immunopathol 1997;85:16-20.
39. Moore KW, de Waal Malefyt R, Coffman RL, et al. Interleukin-10 and the interleukin-10 receptor. Annu Rev Immunol 2001;19:683-765.
40. Marchant A, Deviere J, Byl B, et al. Interleukin-10 production during septicaemia. Lancet 1994;343:707-708.
41. van der Poll T, de Waal Malefyt R, Coyle SM, et al. Antiinflammatory cytokine responses during clinical sepsis and experimental endotoxemia: sequential measurements of plasma soluble interleukin (IL)-1 receptor type II, IL-10, and IL-13. J Infect Dis 1997;175:118-122.
42. O'Dwyer MJ, Mankan AK, Stordeur P, et al. The occurrence of severe sepsis and septic shock are related to distinct patterns of cytokine gene expression. Shock 2006;26:544-550.
43. Czeslick E, Struppert A, Simm A, et al. E5564 (Eritoran) inhibits lipopolysaccharide-induced cytokine production in human blood monocytes. Inflamm Res 2006;55:511-515.
44. Blanque R, Meakin C, Millet S, et al. Hypothermia as an indicator of the acute effects of lipopolysaccharides: comparison with serum levels of IL1 beta, IL6 and TNF alpha. Gen Pharmacol 1996;27:973-977.
45. Hirotani T, Yamamoto M, Kumagai Y, et al. Regulation of lipopolysaccharide-inducible genes by MyD88 and Toll/IL-1 domain containing adaptor inducing IFN-beta. Biochem Biophys Res Commun 2005;328:383-392.
46. Lin WJ, Yeh WC. Implication of Toll-like receptor and tumor necrosis factor alpha signaling in septic shock. Shock 2005;24:206-209.
47. Shuster R, Traub-Dargatz J, Baxter G. Survey of diplomates of the American College of Veterinary Internal Medicine and the American College of Veterinary Surgeons regarding clinical aspects and treatment of endotoxemia in horses. J Am Vet Med Assoc 1997;210:87-92.
48. MacAllister CG, Morgan SJ, Borne AT, et al. Comparison of adverse effects of phenylbutazone, flunixin meglumine, and ketoprofen in horses. J Am Vet Med Assoc 1993;202:71-77.
49. Morresey PR, Mackay RJ. Endotoxin-neutralizing activity of polymyxin B in blood after IV administration in horses. Am J Vet Res 2006;67:642-647.
50. Barton MH, Parviainen A, Norton N. Polymyxin B protects horses against induced endotoxaemia in vivo. Equine Vet J 2004;36:397-401.
51. Spier SJ, Lavoie JP, Cullor JS, et al. Protection against clinical endotoxemia in horses by using plasma containing antibody to an Rc mutant E coli U5). Circ Shock 1989;28:235-248.
52. Durando MM, MacKay RJ, Linda S, et al. Effects of polymyxin B and Salmonella typhimurium antiserum on horses given endotoxin intravenously. Am J Vet Res 1994;55:921-927.